AI has implications across the value chain in oncology, including in the diagnostics space, where agentic AI is making it easier to access and understand genomic data – an advance with applications in ...
Veeva delivers the industry cloud for life sciences with software, AI, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ...
Bristol Myers Squibb has high hopes for its celmod programme for blood cancers, and a phase 3 readout – for mezigdomide in multiple myeloma – has delivered the goods. The cereblon E3 ligase modulator, ...
The UK's National Screening Committee has concluded its review of prostate cancer screening in the UK, saying that the harms of a large-scale, national programme would outweigh the benefits. The ...
From the autumn, pharmacists in England will be able to prescribe a wider array of medicines under a £340 million programme announced by the UK government. The initiative is part of the Pharmacy First ...
Sudden unexpected death is a terrifying consequence faced by people living with uncontrolled tonic-clonic seizures (TCSs), so ...
GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, can achieve a functional cure in 19% of patients, ...
Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...
The FDA has started a priority review of Sanofi's Gaucher disease therapy venglustat, a potentially first-in-class therapy, ...
As clinical research sites come under growing operational pressure, sponsors and CROs are being challenged to rethink how studies are designed and supported. Protocols are becoming more complex.
After its advisory committee voted against AstraZeneca's camizestrant as a treatment for breast cancer in April, the FDA has ...
The FDA has approved AbbVie's Decnupaz, a treatment for rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN) that was one of the assets in its $10.1 billion takeover of ImmunoGen in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results